Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Given Average Recommendation of “Hold” by Analysts

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) have been given an average recommendation of “Hold” by the five research firms that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating on the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $9.40.

RXRX has been the subject of several recent analyst reports. JPMorgan Chase & Co. upgraded shares of Recursion Pharmaceuticals from a “neutral” rating to an “overweight” rating and raised their target price for the stock from $10.00 to $11.00 in a research note on Wednesday, December 17th. Wall Street Zen raised shares of Recursion Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Saturday, February 28th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a report on Thursday, January 22nd. Needham & Company LLC reissued a “buy” rating and set a $8.00 target price on shares of Recursion Pharmaceuticals in a research note on Thursday, February 26th. Finally, Bank of America decreased their price target on Recursion Pharmaceuticals from $7.00 to $6.00 and set a “neutral” rating on the stock in a research note on Wednesday, February 25th.

Insiders Place Their Bets

In other news, CFO Ben R. Taylor sold 7,956 shares of the company’s stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $3.39, for a total transaction of $26,970.84. Following the transaction, the chief financial officer directly owned 1,180,318 shares of the company’s stock, valued at $4,001,278.02. This represents a 0.67% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Blake Borgeson sold 220,000 shares of the company’s stock in a transaction dated Tuesday, February 3rd. The stock was sold at an average price of $4.20, for a total transaction of $924,000.00. Following the transaction, the director owned 6,429,863 shares in the company, valued at $27,005,424.60. The trade was a 3.31% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 511,063 shares of company stock worth $2,135,702. Corporate insiders own 8.43% of the company’s stock.

Institutional Trading of Recursion Pharmaceuticals

Several large investors have recently modified their holdings of RXRX. TD Waterhouse Canada Inc. increased its stake in shares of Recursion Pharmaceuticals by 64.1% during the 2nd quarter. TD Waterhouse Canada Inc. now owns 5,631 shares of the company’s stock worth $29,000 after purchasing an additional 2,200 shares in the last quarter. International Assets Investment Management LLC purchased a new stake in Recursion Pharmaceuticals in the 4th quarter valued at approximately $31,000. Sequoia Financial Advisors LLC acquired a new stake in Recursion Pharmaceuticals during the 4th quarter valued at $41,000. Allworth Financial LP increased its position in Recursion Pharmaceuticals by 85.6% during the third quarter. Allworth Financial LP now owns 9,548 shares of the company’s stock worth $47,000 after buying an additional 4,403 shares in the last quarter. Finally, IFP Advisors Inc raised its holdings in shares of Recursion Pharmaceuticals by 81.5% in the third quarter. IFP Advisors Inc now owns 10,355 shares of the company’s stock worth $51,000 after acquiring an additional 4,650 shares during the last quarter. 89.06% of the stock is currently owned by institutional investors and hedge funds.

Recursion Pharmaceuticals Stock Performance

Shares of RXRX stock traded down $0.15 during midday trading on Friday, hitting $3.01. The company had a trading volume of 4,422,575 shares, compared to its average volume of 18,748,900. The stock has a market cap of $1.58 billion, a price-to-earnings ratio of -2.03 and a beta of 0.97. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.50 and a quick ratio of 5.50. The company’s 50 day simple moving average is $3.77 and its 200 day simple moving average is $4.49. Recursion Pharmaceuticals has a 52-week low of $2.98 and a 52-week high of $7.18.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings results on Wednesday, February 25th. The company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.28) by $0.07. Recursion Pharmaceuticals had a negative return on equity of 63.98% and a negative net margin of 863.37%.The business had revenue of $35.54 million during the quarter, compared to analysts’ expectations of $24.56 million. During the same quarter in the prior year, the business earned ($0.53) earnings per share. The company’s quarterly revenue was up 671.7% compared to the same quarter last year. Research analysts anticipate that Recursion Pharmaceuticals will post -1.57 earnings per share for the current fiscal year.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.